Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A better understanding of its mechanism will allow for the development of assays to monitor its clinical efficacy and safet...
Main Authors: | Elizabeth A. Mills, Magdalena A. Ogrodnik, Andrew Plave, Yang Mao-Draayer |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-01-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2018.00005/full |
Similar Items
-
Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
by: Dipen Sangurdekar, et al.
Published: (2019-11-01) -
Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation
by: S. K. Vainio, et al.
Published: (2022-02-01) -
Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View
by: Elizabeth A. Mills, et al.
Published: (2018-02-01) -
Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01) -
Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration
by: Smathorn Thakolwiboon, et al.
Published: (2023-10-01)